JohannaChockBendellMD

Oncology • Nashville, TN

Physician

Join to view full profile

Are you Dr. Bendell?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 72 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
250 25th Ave N
Ste 100
Nashville, TN 37203
Phone+1 615-320-5090
Is this information wrong?

Summary

Dr. Johanna Bendell, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee, North Carolina, and Florida. She is affiliated with TriStar Centennial Medical Center and Ascension Saint Thomas.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2020 - Present
TN State Medical License 2008 - 2023
NC State Medical License 2020 - 2022
MA State Medical License 2000 - 2005

Clinical Trials

Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 2
Study of Perifosine + Capecitabine for Colon Cancer Patients Start of enrollment: 2009 Oct 01
Completed
Phase 1
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer Start of enrollment: 2010 Apr 01
Completed
Phase 3
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Start of enrollment: 2010 May 01
Completed
Phase 2
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer Start of enrollment: 2010 Jul 01
Completed
Phase 1
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Start of enrollment: 2010 Jul 20
Completed
Phase 1, Phase 2
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Start of enrollment: 2010 Dec 01
Completed
Phase 2
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors Start of enrollment: 2010 Nov 01
Completed
Phase 1
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
Completed
Phase 1, Phase 2
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
Completed
Phase 1, Phase 2
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors Start of enrollment: 2011 Apr 01
Completed
Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2012 Nov 23
Completed
Phase 2
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC Start of enrollment: 2013 Jun 19
Completed
Phase 1
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 1
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Start of enrollment: 2014 May 05
Completed
Phase 1
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors Start of enrollment: 2014 Apr 01
Terminated
Phase 1, Phase 2
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Start of enrollment: 2014 Jul 01
Completed
Phase 2
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
Completed
Phase 2
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Start of enrollment: 2015 Jul 29
Completed
Phase 1
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
Completed
Phase 1
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors Start of enrollment: 2015 Nov 06
Completed
Phase 1
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28
Completed
Phase 3
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 15
Completed
Phase 1
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Start of enrollment: 2017 Jul 28
Terminated
Phase 2
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Start of enrollment: 2017 Jan 12
Completed
Phase 2
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Start of enrollment: 2017 Jun 22
Completed
Phase 1, Phase 2
PRS-343 in HER2-Positive Solid Tumors Start of enrollment: 2017 Sep 28
Completed
Phase 1
MGD009/MGA012 Combination in Relapsed/Refractory Cancer Start of enrollment: 2018 Feb 27
Completed
Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Start of enrollment: 2018 May 02
Recruiting
Phase 1, Phase 2
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Start of enrollment: 2018 Dec 19
Completed
Phase 1
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread Start of enrollment: 2019 Dec 23
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

6 citations
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Tae Won Kim, Philippe L Bedard, Patricia LoRusso, Michael S Gordon, Johanna Bendell, Do-Youn Oh, Myung-Ju Ahn, Elena Garralda, Sandra P D'Angelo, Jayesh Desai, F Steph...> ;JAMA Oncology. 2023 Nov 1
2 citations
Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer.
Lucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, Junghyun Lim, Kerrigan Blake, Noelyn Kljavin, Sarah Gierke, Alexis Scherl, James Ziai, Erin McNamara, Mark Owyong, S...> ;Nature Communications. 2023 Sep 23
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Jason J Luke, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer,...> ;British Journal of Cancer. 2023 Jun 1
12 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M Noonan, Dong-Wan Kim, John H Strickler, Sang-We Kim, Stephen Clarke, Thomas J George, Peter S Grimison, Mina...> ;Cancer Immunology, Immunotherapy. 2023 Jul 1
2 citations
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Shah, M., Yoshino, T., Tebbutt, N., Grothey, A., Tabernero, J., Xu, R., Cervantes, A., Oh, S., Yamaguchi, K., Fakih, M., Falcone, A., Wu, C., Chiu, V., Tomasek, J., Be...> ;Clinical Colorectal Cancer. 2023 Mar 1
1 citations
Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial.
Cláudia S Ferreira, Galina Babitzki, Irina Klaman, Oliver Krieter, Katharina Lechner, Johanna Bendell, Suzana Vega Harring, Florian Heil> ;Frontiers in Oncology. 2023 Jan 1
15 citations
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Emerson A Lim, Johanna C Bendell, Gerald S Falchook, Todd M Bauer, Charles G Drake, Jennifer H Choe, Daniel J George, Janet L Karlix, Susanna Ulahannan, Kris F Sachsen...> ;Clinical Cancer Research. 2022 Nov 14
7 citations
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xi...> ;The Oncologist. 2022 Nov 3
22 citations
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Monta...> ;Clinical Cancer Research. 2022 Aug 2
10 citations
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Christopher J Sweeney, Ivor J Percent, Sunil Babu, Jennifer L Cultrera, Bryan A Mehlhaff, Oscar B Goodman, David S Morris, Ian D Schnadig, Costantine Albany, Neal D Sh...> ;Clinical Cancer Research. 2022 Jun 1
1 citations
Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.
Stephanie J Yaung, Christine Ju, Sandeep Gattam, Alan Nicholas, Nicolas Sommer, Johanna C Bendell, Herbert I Hurwitz, John J Lee, Fergal Casey, Richard Price, John F P...> ;Cancers. 2022 Apr 29
19 citations
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Funda Meric-Bernstam, Nizar M Tannir, Othon Iliopoulos, Richard J Lee, Melinda L Telli, Alice C Fan, Angela DeMichele, Naomi B Haas, Manish R Patel, James J Harding, M...> ;Clinical Cancer Research. 2022 Apr 14
24 citations
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler, Kathleen N. Moore, Robert J. Stagg, Ann M. Kapoun, Leonardo...> ;Clinical Cancer Research. 2021 Nov 29
20 citations
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Hamid Emamekhoo, Mark R. Olsen, Bradley Curtis Carthon, Alexandra Drakaki, Ivor John Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash ...> ;Cancer. 2021 Nov 16
20 citations
Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels
, , , , , , , , , , , , , , , , , , , , , , > ;Science Advances. 2021 Oct 8
18 citations
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Samuel J. Klempner, Johanna C. Bendell, Victoria M. Villaflor, Laura LaNiel Tenner, Stacey Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey...> ;Molecular Cancer Therapeutics. 2021 Sep 4
10 citations
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
Kathleen N. Moore, David S. Hong, Manish R. Patel, Shubham Pant, Susanna Varkey Ulahannan, Suzanne F. Jones, Funda Meric-Bernstam, Judy S. Wang, Raid Aljumaily, Erika ...> ;Targeted Oncology. 2021 Sep 1
17 citations
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors.
David G. DeNardo, Anna Galkin, Jakob Dupont, Lei Zhou, Johanna C. Bendell> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
181 citations
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin Kate Kelley, Bruno Sangro, William P. Harris, Masafumi Ikeda, Takuji Okusaka, Yoon-Koo Kang, Shukui Qin, David Wai-Meng Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Y...> ;Journal of Clinical Oncology. 2021 Jul 22
36 citations
Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 8...
Romain Cohen, Q. Shi, Jeffrey P. Meyers, Zhaohui Jin, Magali Svrcek, Charles S. Fuchs, Félix Couture, P. Kuebler, Kristen K. Ciombor, Johanna C. Bendell, A. De Jesus-A...> ;Annals of Oncology. 2021 Oct 1
15 citations
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding...
Rachel E. Sanborn, Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna C. Bendell, Karen A. Autio, Daniel C. Cho, Ruth...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
22 citations
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung Naing, Fiona C Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina B...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
11 citations
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Nuria Kotecki, P. Vuagnat, Bert H. O'Neil, Shadia I. Jalal, Sylvie Rottey, Hans Prenen, Karim A. Benhadji, Meng Xia, Anna M. Szpurka, Abhijoy Saha, Johan Wallin, Subha...> ;Journal of Immunotherapy. 2021 Apr 28
53 citations
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) ...
Jeffrey A. Meyerhardt, Qian Shi, Charles S. Fuchs, Jeffrey G. Meyer, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, Katherine A. Guthrie, Félix Couture, Philip Kuebl...> ;JAMA. 2021 Apr 6
44 citations
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei, Nathan O. Siemers, Dimple Pandya, Han Chang, Teresa Sanchez, Christopher T. Harbison, Péter Szabó, Yelena Y. Janjigian, Patrick A. Ott, Padmanee Sharma, Joha...> ;Clinical Cancer Research. 2021 Mar 29
Join now to see all

Press Mentions

Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical TrialsMay 20th, 2022
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic CancerJanuary 15th, 2021
Gastrointestinal Cancers | Current Concepts and Recent Advances in Oncology Part 4: Gastrointestinal CancerDecember 30th, 2020
Join now to see all

Hospital Affiliations

Ascension Saint ThomasNashville, Tennessee
TriStar Centennial Medical CenterNashville, Tennessee